Calling the lowest-risk prostate cancers something else may encourage some patients to follow physicians’ treatment recommendations of active surveillance and avoid pursuing more aggressive options, according to a growing number of physicians advocating for a change in nomenclature, The Wall Street Journal reported Jan. 24.
